Alembic Pharmaceuticals, a well-known pharmaceutical company, announced that its bioequivalence facility in Vadodara, Gujarat, was recently inspected by the United States Food and Drug Administration (US FDA). The inspection took place from March 3 to March 7, 2025.
After the inspection, the US FDA issued a Form 483 with one procedural observation regarding the company’s operations at this facility. A Form 483 is a notice from the US FDA that highlights any issues found during an inspection that may not meet regulatory standards.
In a statement released after market hours on Friday, Alembic Pharmaceuticals confirmed that the issue was procedural and assured that it would submit a detailed response to the US FDA within the required time frame. The company did not provide specific details about the observation but mentioned that it would take necessary corrective actions, which is a normal part of the regulatory process.
Despite this news, Alembic Pharmaceuticals’ stock rose by 4.26% on the Bombay Stock Exchange (BSE), closing at Rs 845.65.
Financial Performance
Alembic Pharmaceuticals has faced some financial challenges recently. In Q3 FY25 (October-December 2024), the company’s consolidated net profit dropped by 23.29% to Rs 138.42 crore, compared to Rs 180.45 crore in the same period last year (Q3 FY24). However, the company’s revenue from operations increased by 3.81% year-on-year (YoY) to Rs 1,692.74 crore, showing growth in its core business.
Read More: Shilpa Medicare’s Raichur Unit Receives US FDA Form 483: What It Means for the Pharma Giant
What’s Next for Alembic?
Alembic’s response to the US FDA’s observation and its efforts to maintain regulatory compliance will be crucial for its global business. The company remains focused on following international standards, which is important for investor confidence and future growth.
Although the US FDA’s observation is a concern, the stock market’s positive reaction suggests that investors believe Alembic will handle the situation well. Stakeholders will be closely watching how the company resolves this issue and its performance in the coming months.
